Glyceryl-Trinitrate-Induced Headache in Patients With Familial Hemiplegic Migraine

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00541736

Enrollment

Registered

2007-10-10

Start date

2007-10-31

Completion date

2008-05-31

Last updated

2008-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Familial Hemiplegic Migraine

Keywords

Familial Hemiplegic Migraine

Brief summary

The aim of the present study is to explore the importance of migraine genes on the headache/migraine responses after GTN in FHM-patients and healthy volunteers.

Detailed description

Glyceryl trinitrate (GTN) induces migraine attacks indistinguishable from spontaneous attacks in approximately 80% of migraine sufferers. After systemic administration GTN is transformed to nitric oxide (NO). Treatment of spontaneous migraine attacks with an inhibitor of NO is effective in 60% of patients. These data show that NO is involved in both initiation and maintenance of migraine attack. The importance of migraine genes is disputed. Evidence from FHM patients with known mutations indicates that migraine pathways in FHM may be different from normal migraine. The aim of the present study is to examine whether this difference also exists in FHM patients without known mutations. The project will improve our understanding of the neurobiology of migraine and stimulate development of new treatment targets.

Interventions

DRUGNitroglycerine

Nitroglycerine infusion over 20 minutes: 0.5 ug/kg/min

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

BASIC_SCIENCE

Masking

NONE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Yes

Inclusion criteria

* Diagnosis of familial hemiplegic migraine (IHS-classification criteria)

Exclusion criteria

Patients and controls: * A history of cerebrovascular disease and other CNS- disease * A history of serious somatic and mental disease * A history suggesting ischaemic heart disease * A history of hypo- or hypertension * Daily intake of medication apart from oral contraceptives * Abuse of alcohol or medicine (opioid analgesics). * Pregnant or breastfeeding women. On the study day: * No intake of a simple analgesic in the previous 48 hours * No headache in the previous 48 hours

Design outcomes

Primary

Measure	Time frame
Migraine and associated symptoms	0-14 h
Migraine aura	0 - 14 h

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026